DelveInsight’s “COVID-19 Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the COVID-19 pipeline landscapes. It comprises COVID-19 pipeline drug profiles, including clinical and non-clinical stage products. It also includes the COVID-19 therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive COVID-19 pipeline products.
Some of the key takeaways of the COVID-19 Pipeline Report:
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as, Amgen, Corvus Pharmaceuticals, Fulcrum Therapeutics, Synairgen Research. Revive Therapeutics, Novavax, Valneva, etc., are developing therapies for the treatment of COVID-19.
Emerging therapies such as Otezla (Apremilast), CPI-006, Losmapimod, SNG001 (Interferon beta-1a), Bucillamine, NVX-CoV2373, VLA2001, are expected to have a significant impact on the COVID-19 market in the coming years.
Get an overview of pipeline landscape @ COVID-19 Clinical Trials Analysis
COVID-19 Overview
COVID-19 is an infectious disease caused by a newly discovered coronavirus, i.e., SARS-CoV-2. It spreads primarily through droplets of saliva or discharge from the nose when an infected person coughs or sneezes. CoVs are enveloped, positive-stranded RNA viruses with nucleocapsids. The pathogenic mechanism which causes pneumonia seems to be complex
COVID-19 Emerging Drugs
Otezla (Apremilast): Amgen
CPI-006: Corvus Pharmaceuticals
Losmapimod: Fulcrum Therapeutics
SNG001 (Interferon beta-1a): Synairgen Research
Bucillamine: Revive Therapeutics
NVX-CoV2373: Novavax
VLA2001: Valneva
For further information, refer to the detailed report @ COVID-19 Pipeline Therapeutics
Scope of COVID-19 Pipeline Drug Insight
Coverage: Global
Major Players: Amgen, Corvus Pharmaceuticals, Fulcrum Therapeutics, Synairgen Research. Revive Therapeutics, Novavax, Valneva, and others.
Pipeline Therapies: Otezla (Apremilast), CPI-006, Losmapimod, SNG001 (Interferon beta-1a), Bucillamine, NVX-CoV2373, VLA2001, and others.
Table of Contents
1
COVID-19 Report Introduction
2
COVID-19 Executive Summary
3
4
COVID-19- Analytical Perspective In-depth Commercial Assessment
5
COVID-19 Pipeline Therapeutics
6
COVID-19 Late Stage Products (Phase II/III)
7
COVID-19 Mid Stage Products (Phase II)
8
COVID-19 Early Stage Products (Phase I)
9
COVID-19 Preclinical Stage Products
10
COVID-19 Therapeutic Assessment
11
COVID-19 Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
COVID-19 Key Companies
14
COVID-19 Key Products
15
COVID-19 Unmet Needs
16
COVID-19 Market Drivers and Barriers
17
COVID-19 Future Perspectives and Conclusion
18
COVID-19 Analyst Views
19
Appendix
20
About DelveInsight
Get a customized pipeline report @ COVID-19 Drugs Pipeline Report
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/